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ABSTRACT
Objectives: To develop a computerised decision aid
(DA) to inform the decision process on adjuvant
chemotherapy in patients with stage II colorectal
cancer, and examine perceived usefulness, acceptability
and areas for improvement of the DA.
Design: Mixed methods.
Setting: Single outpatient oncology department in
central London.
Participants: Consecutive recruitment of 13 patients
with stage II colorectal cancer, 12 of whom completed
the study. Inclusion criteria were: age >18 years;
complete resection for stage II adenocarcinoma of the
colon or rectum; patients within 14–56 days after
surgery; no contraindication to adjuvant chemotherapy;
able to give written informed consent. Exclusion
criterion: previous chemotherapy.
Primary outcomes: Patient perceived usefulness
(assessed by the PrepDM questionnaire) and
acceptability of the DA.
Results: PrepDM scores, measuring the perceived
usefulness of the DA in preparing the patient to
communicate with their doctor and make a health
decision, were above those reported in other patient
groups. Patient acceptability scores were also high;
however, interviews showed that there was evidence of
a lack of understanding of key information among
some patients, in particular their baseline risk of
recurrence, the net benefit of combination
chemotherapy and the rationale for having
chemotherapy when cancer had apparently gone.
Conclusions: Patients found the DA acceptable and
useful in supporting their decision about whether or
not to have adjuvant chemotherapy. Suggested
improvements for the DA include: sequential
presentation of treatment options (eg, no treatment vs
1 drug, 1 drug vs 2 drugs) to enhance patient
understanding of the difference between combination
and single therapy, diagrams to help patients
understand the rationale for chemotherapy to prevent a
recurrence and inbuilt checks on patient understanding
of baseline risk of recurrence and net benefit of
chemotherapy.
INTRODUCTION
Ethical considerations and recent policy
changes have put patients at the centre of
health decisions, aiming to make
shared-decision-making ‘the norm’.1 2 One
key issue for people who have undergone
surgical resection of colorectal cancer is the
decision about whether or not to have adju-
vant chemotherapy, which is typically either
5-FU or capecitabine, given alone or in com-
bination with oxaliplatin.3 4 While surgery is
highly effective for localised disease, up to
85% of patients with lymph node involve-
ment (stage III) relapse within 5 years. Since
chemotherapy can prevent recurrence in up
to 25% of patients with stage III disease,5 it is
offered routinely. For patients without lymph
node involvement (stage II), the risk of
relapse is lower (20–40%) and a smaller
number of patients (3–7%) are expected to
beneﬁt.6 7 Since there is a risk of side effects
following chemotherapy, some of which can
be life-threatening or permanent and the
balance of harms and beneﬁts is marginal in
Strengths and limitations of this study
▪ This study evaluated patient acceptability, per-
ceived usefulness and understanding of a deci-
sion aid (DA) using mixed-methods at the point
patients made their decision about whether or
not to have adjuvant chemotherapy.
▪ We recruited men and women with a range of
different ages and levels of education, including
people with no educational qualifications, enab-
ling us to capture a range of different responses
to the DA.
▪ People educated to degree level or above were
over-represented in the study, and this may have
led to an overestimate of perceived usefulness
and acceptability of the DA.
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patients with stage II, the use of adjuvant chemotherapy
in this patient group has remained controversial.8
Patients with colorectal cancer have expressed a desire
for more information, notably about their cancer, progno-
sis and treatment options,9 10 and effective communica-
tion of diagnostic and prognostic information has been
shown to enhance patient well-being and patients’ per-
ceptions of the quality of doctor–patient interactions.11
However, patients can hold more positive views on adju-
vant therapy than physicians12 and may want chemother-
apy even when there is little evidence that it will help
prevent a recurrence;13 14 for example, women with
breast cancer with a low risk of recurrence are more
likely to decline chemotherapy if they are aware of the
(small) impact,15 underlining the need for effective com-
munication. People have problems understanding risk
information,16 and while there is an emphasis on patients
making decisions that are consistent with their values, evi-
dence points to the instability of preferences, with some
researchers arguing that true preferences may not always
exist, but are constructed ‘on the spot’ using the informa-
tion available at the time of decision-making.17
Decision aids
To facilitate informed decision-making, a wide range of
decision aids (DAs) have been developed. DAs are used
alongside patient–physician interactions and contain
detailed information about clinical options and out-
comes, are explicit about the choices facing the patient
and encourage patients to express their preference. DAs
typically result in greater knowledge, a higher propor-
tion of people with accurate risk perceptions, lower deci-
sional conﬂict (eg, feeling better informed and clearer
about personal values) and more active roles in decision-
making compared with usual care.18 Although DAs have
been developed to aid treatment decisions for a number
of different cancers,19–22 little research has been done in
the context of colorectal cancer. One exception is a
booklet to help patients make decisions about adjuvant
chemotherapy or radiotherapy, although this was only
evaluated among patients who had opted to have adju-
vant therapy, and was developed to be used by the
patient at home rather than as part of a clinical
consultation.10 23
The aim of the present study was to develop a DA for
chemotherapy for stage II that included the information
identiﬁed as important to patients in previous
research9 10 and examine its usefulness and acceptability
to patients making a decision about whether or not to
have adjuvant chemotherapy, as well as to identify any
areas where patient understanding of key information
could be improved.
METHODS
Development of the DA
PROforma decision support technology (a formal lan-
guage for automating clinical processes and protocols)
and the Tallis tool set (used to design the decision
support, check the syntactic integrity of the programme
and run the application in a test environment) were
used to develop the DA;24 25 http://openclinical.net/
index.php?id=390. A variety of decision support applica-
tions based on PROforma technology have demon-
strated a signiﬁcant positive impact on a number of
outcome measures such as reducing prescription errors
and adherence to evidence-based guidelines.26–28
The DA captured patient demographic and clinical
information (eg, histology type, evidence of extramural
vascular invasion), as well as patient ﬁtness to undergo
chemotherapy (assessed via the presence of comorbidity
and ECOG performance status29 ranging from ﬁt and
well (0) to bed bound (4)).
Risk of recurrence with and without chemotherapy
was mathematically derived based on: (1) the baseline
risk of recurrence without chemotherapy, which was cal-
culated for each patient using information from the
published SEER database (http://seer.cancer.gov/data/)
using the adjuvant!online risk calculator (http://www.
adjuvantonline.com);30 and (2) the effectiveness of
single and combination chemotherapy, taken from pub-
lished randomised controlled trials and meta-analysis.6 7
This calculator matches baseline risk of recurrence data
to the individual patient’s clinicopathological character-
istics (T stage, number of lymph nodes examined, hist-
ology type and histopathological grading). The
age-speciﬁc natural mortality was derived from published
national mortality data.
In line with the presentation of information in
Adjuvant!online, and consistent with recommendations,
we used a simple percent format, and absolute risk
when conveying information about the net beneﬁt of
chemotherapy along with a bar chart showing the likeli-
hood of different outcomes, thereby using visual and
numeric information to convey risk of recurrence infor-
mation, keeping the denominator consistent and stating
the reference class and time frame.31 32
Patients were ﬁrst shown one graph detailing their
baseline risk of recurrence in the absence of chemother-
apy (see ﬁgure 1) and graphs showing the net beneﬁt of
single and combination chemotherapy on the ﬁnal page
of the DA (see ﬁgure 2). Since the risk prediction of
Adjuvant!online does not include clinical presentation
(obstruction or perforation), or the risk factors vascular,
lymphovascular and perineural invasion, these were
included under headings for ‘indicators for good prog-
nosis’ (eg, tumour stage T3) and ‘indicators for bad
prognosis’ (eg, extramural vascular invasion), presented
on the ﬁnal page of the DA (see ﬁgure 2).
Information about the method of administration for
the different drugs, the need for the insertion of a
central line, the number of times the patient would
need to come to hospital and the duration of treatment
was given. The list of side effects were put into three dif-
ferent sections: common (>30% of patients affected),
less common but serious (potentially life-threatening)
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and potentially permanent side effects. It was made
clear that the ﬁrst two sections related to all chemother-
apy options, but that the long-term side effects only
related to the two-drug chemotherapy option (oxalipla-
tin carries a high risk of long-term numbness of the
hands and feet).4
The values clariﬁcation exercise was adapted from one
developed for use in colorectal cancer screening among
elderly people33 to capture the main issues involved in
the decision, including features identiﬁed as important
to patients with colorectal cancer9 (see online
supplementary table S1). Patients were asked to com-
plete the questionnaire on the computer, selecting 1 of
the 2 options presented for all 10 questions. Patients
were able to review and change their responses to the
questions at any time during or after the consultation.
The ﬁnal page of the DA combined graphical presen-
tation of risk of recurrence information for the three
treatment options alongside arguments laying out the
pros and cons for each option, and the results of the
values clariﬁcation exercise (see ﬁgure 2).
Design
A mixed methods design was employed.
Participants
Potential patients were identiﬁed at the colorectal multi-
disciplinary team meeting at the Royal Free NHS Trust.
Inclusion criteria were: male or female patients aged
>18 years; patients who had undergone complete resec-
tion for stage II adenocarcinoma of the colon or
rectum; patients within 14–56 days after surgery; no
contraindication to adjuvant chemotherapy; able to give
written informed consent. The exclusion criterion was
previous chemotherapy. Target N was 12 in line with
similar research on DAs.34 Patients were recruited
consecutively.
Procedures
After informed consent, patients were randomised to
receive the DA at either the ﬁrst or second consultation.
All patients were given written information about the
side effects of chemotherapy, as per current practice.
When seen back in clinic, after 1–2 weeks, patients were
given the opportunity to ask questions, at which point
the patient’s treatment decision was recorded. Patients
were invited to complete the values clariﬁcation exercise
on the computer, but received help from relatives or the
clinician if requested.
All consultations took place in the Outpatients
Oncology Department at the Royal Free London NHS
Trust. Patients were given a questionnaire assessing
responses to the DA after the consultation at which the
DA had been used.
Questionnaire
Information about age, gender, educational level, ethni-
city and employment status was collected. Perceived use-
fulness of the DA in preparing the patient to
communicate with their doctor and make a health deci-
sion was assessed with the PrepDM questionnaire, a
10-item scale designed to measure the usefulness of DAs,
developed across a number of different patient groups,
including patients with cancer, with good internal reliabil-
ity and validity.35 Cronbach’s α in this study was 0.935.
Example items include: ‘Did the decision aid…Help you
Figure 1 Graph showing baseline risk of recurrence.
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think about the pros and cons of each option? … Help
you identify questions you want to ask your doctor?’
Response options are on a ﬁve-point Likert scale with
higher scores indicating higher agreement. Acceptability
of the DA was assessed using seven items; three were from
Bennett et al,35 while the remaining items were developed
for this study (see table 1 for questions and response
options). Data were analysed using SPSS V.22.
Interview
Face-to-face interviews were used to gain an in-depth
understanding of patients’ responses to the DA, and
their understanding of key information. These were con-
ducted face to face at the hospital following the second
consultation, between March 2012 and July 2014, by
AMi, who has experience of conducting interviews with
patients with colorectal cancer,36 and was not involved in
the patients’ care. The interviews lasted an average of
33 min (range: 18–54) and were recorded and tran-
scribed verbatim by a transcription company, and
reviewed for accuracy by AMi using the original record-
ings. The initial Topic Guide is provided as online
supplementary data, but during the interviews, it
became clear that patients were confused about what
Figure 2 Final page of decision aid showing risk of recurrence and net benefit of treatment options alongside pros and cons of
different treatment options.
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risk of recurrence meant and how chemotherapy could
act on the body to prevent this. Subsequent patients
were therefore asked about these issues in more detail.
Data were analysed using thematic analysis,37 facilitated
by the software package NVIVO V.10. AMi developed the
codes by examining all instances in the data set that
related to the DA, risk of recurrence information and
the rationale for having chemotherapy. Themes were
derived and developed via an iterative process, with con-
stant comparisons of the data that identiﬁed similarities
and differences within and across individual interviews.
The codes and supporting quotes were reviewed for
appropriateness and accuracy by AMa. Patients were not
asked to verify the thematic analysis as we did not wish
to increase participation burden.
RESULTS
Fifteen patients were approached by clinic staff, 13 were
recruited, with 12 completing the study. The age of par-
ticipants ranged from 33 to 82, with a median age of 67.
The ratio of men to women was 1:2. Over half (n=7)
were educated to degree level or equivalent and the
majority were of white ethnicity (British or Irish) (n=9).
Approximately half were employed (n=6), one was
unemployed and the remainder were retired. One
patient reported having had chemotherapy prior to
surgery (s6). This person was included since it was not
felt to impact on the reported outcomes. Eleven of the
12 patients declined chemotherapy (all except s8).
Patients’ perceptions of the usefulness of the DA in
helping them communicate with their doctor and make
a decision were good, with scores (mean 4.28, SD 0.9)
comparing favourably with those reported in other clin-
ical populations, where scores ranged from 3.3 to 3.9.35
Patients also reported ﬁnding the risk of recurrence
information in the DA and graphical representation of
information in the DA helpful, with all except one
reporting that they were happy they understood the
meaning of the information in the DA about risk of
recurrence (see table 1).
Graphical representation of information on risk
A number of patients felt the graphs increased the
clarity of the risk of recurrence information, “I liked the
graphs, I suppose they’re accurate really… I worked with
statistics enough to know that you can kind of hide the
numbers…. it made me consider chemotherapy more
than I possibly would if I was just given words” (s10).
Another participant described how the graphical presen-
tation looked more scientiﬁc and hence more credible
than being told the same information verbally: “Really
it’s no different to what the surgeon had already told us
yesterday… it’s a very much more scientiﬁc, you know,
sort of presentation to it…” (s4).
For some patients, the graphs provided information
they would otherwise have overlooked: for one patient, it
was the additional beneﬁt conferred by two, compared
with one, chemotherapy drug “I didn’t realise that the
one was quite like a signiﬁcant difference there, between
the two (chemotherapy drugs)” (s3); for another
patient, it was the risk of death from other causes:
“When we’re there we only talk about coming back
and not coming back. But we do know that death is
something that can come anytime… So I just put them
in the two categories but on the graph I saw the three
there” (s9).
Some patients found it helpful to see the portion of
the graph that illustrated the net beneﬁt of chemother-
apy, whether they wanted chemotherapy or not, and
used it to help them cope with their decision: “that
made me feel quite positive… even though there was
only 5%… I’m going into the chemotherapy, now, think-
ing about that line” (s8), “the graph…the bit that she
Table 1 Perceived usefulness and acceptability of the
decision aid
Number
Usefulness of information in preparing patient
for decision (PrepDM) (1–5) mean (SD)
4.28 (0.90)
Acceptability of DA35
Helpful
Very 10
Somewhat 1
A little 1
Not helpful 0
Recommend to others
Definitely yes 6
Probably yes 5
Probably not 1
Definitely not 0
Information clear
Everything clear 8
Mostly clear 4
Some clear 0
Mostly unclear 0
Did the DA add anything to the consultation
An extreme amount 1
Very much 7
A moderate amount 4
A little bit 0
Nothing 0
Graphical representation in the DA helpful
Extremely 4
Very 6
Moderately 2
A little bit 0
Not at all 0
Understood risk of recurrence info. in DA
Yes 10
No 0
Not sure 1
Helpfulness of risk of recurrence info. in DA
Extremely 3
Very 6
Moderately 1
A little bit 1
Not at all 0
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was talking about (net beneﬁt of chemotherapy) is just
tiny is quite good” (s3).
Some patients liked the positive information about
their general prognosis—“I was quite pleased to see that.
That was nice. There was lots of green (baseline risk of
recurrence)” (s8). One person liked it because they
described themselves as ‘a visual person’ (s3).
However, not everyone was able to articulate whether
or why they had found the graphical information
helpful, particularly if they had taken a younger relative
into the consultation with them and felt conﬁdent their
relative understood what was being said. “I didn’t really
understand it very much…I’m a bit of a dinosaur… I
know my niece would have understood it all” (s11), “I
just can’t say…My son was with me now and he was very
informative afterwards, he was, talked about it a lot…I
think he found it very helpful” (s12).
Values clarification
The belief that they could not predict whether they
would beneﬁt from chemotherapy, the small risk of
cancer coming back and the long-term side effects of
chemotherapy were the main barriers to chemotherapy
(see online supplementary table S2). Of least concern
were the short-term side effects, insertion of a central
line and repeat attendance at hospital, although around
half were still concerned about these things.
Reactions to the values clariﬁcation exercise were
more mixed than to the graphical display. Some patients
found it helpful, while others reported conﬂicting feel-
ings about the information. Positive reactions included
the feeling that it was an accurate reﬂection of their
(often mixed) views about chemotherapy, was clearer,
more explicit, more rational and less emotional, and
empowering for the patient: “it’s good in terms of some-
times you struggle to articulate why you make one deci-
sion versus another” (s10) “getting me to kind of click
on things, and say yes… puts the onus on me to make a
decision and own my decision and feel empowered to
make a decision independent of what the doctor
thinks…” (s8). “Rather than having an emotional
response, there’s an actual ﬁgure there to say, ‘This is
what you decided.’ …it’s good to be logical” (s3).
Others commented on the fact that not all the items
were equally important and that numbers for and
against chemotherapy were a bit simplistic, or having to
select a choice yes/no without saying why did not tell
the whole story.
One patient reported feelings of guilt when answering
the values clariﬁcation exercise, because although they
viewed their health as important they were opting to do
something that did not necessarily maximise their
chances of maintaining their health: “my health comes
ﬁrst above everything. And so a lot of questions there
made me feel when I opted for a different answer to
that, to really putting that ﬁrst, I felt very guilty about,
which was quite interesting. And I did pause and stress
about that a little bit… But just because I answered the
other way doesn’t mean I still don’t have my health, you
know, at the forefront of my thoughts… However, there
are other issues at stake here” (s4).
Another felt it highlighted the importance of life over
everything else: “I’m worrying about hair loss and this
and that…. And what about that? Is that more important
than life itself? Well, no, it isn’t… But that tool…did
think, you know, all of that is trivial in comparison with
life itself. It’s very precious” (s7).
However, one woman felt she only needed the risk of
recurrence statistics to make a decision, and did not
need the values clariﬁcation exercise: “It didn’t seem to
be difﬁcult to answer really…. the biggest thing that
sticks out in my mind is the statistics and the fact that
taking the chemo again made really very little differ-
ence, that my mind was pretty well made up straight
away” (s6). Others forgot whether or not they had per-
formed the exercise: “In all honesty, I’d forgotten that,
you know. I don’t remember I did or not do” (s11).
Patient understanding of risk of recurrence statistics
The majority of patients understood that the aim of
chemotherapy was to reduce the chances of cancer
coming back, although people were more likely to
mention the ﬁgure for net beneﬁt of one chemotherapy
drug (2–3%) rather than two (5%): “if I had chemother-
apy, my chances of living more than ﬁve years would be
about one or two percent increased, compared with not
doing anything” (s1). “The chance of the cancer
coming back was low—without the chemo, was low,
anyway… Yes, the chemo might improve it by a couple
of percent” (s4).
Two patients (both in their 30s) reported higher net
beneﬁt of chemotherapy ﬁgures (of 5%) and a clearer
understanding of the difference between one and two
chemotherapy drugs. “I think off the top of my head
there was 86% chance of it not recurring within ﬁve
years if I stopped it now… then for every additional
drug chemo that I had was approximately a 2.5% add-
itional chance of survival” (s10). One patient confused
net beneﬁt (additional 2–5% avoid recurrence) with
overall recurrence rates (20–40%). “(Oncologist’s name)
said to me, ‘There’s just 2% chance.’ When I’d said,
‘No, I do not want chemo,’…. I took for granted that
sort of the chances of it coming back is extremely low”
(s11).
Patient understanding of how and why cancer recurs and
how chemotherapy may act to reduce risk of recurrence
There was confusion over whether the ﬁgures about
recurrence referred to another primary cancer or pro-
gression of the current episode, or both. “Was it a recur-
rence of the same cancer or was it from somewhere
else?” (s6). While some patients understood that any
recurrence would potentially be more aggressive and
harder to treat than their colorectal cancer had been,
others assumed the recurrence would be in the gut:
“When you say it’s a recurrence, you presume it will be
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expected to be from the same site where the primary
is… somewhere in the gut…” (s6). “Actually, in the
beginning I was thinking that they were talking about
that, the cancer will affect my bowel again. But from
what she’s (the oncologist) saying…it’s not only the
bowel, but you can get other type of cancer” (s9).
“Obviously if it comes back it’s not going to be as
straightforward… It wouldn’t be as simple as just having
an operation and removing it, cos it might go to another
part of the body” (s7).
An additional area of confusion was whether they
were currently cancer free or not, and the rationale for
giving chemotherapy when no cancer was apparently
present or if you were a person ‘prone’ to cancer.
“People say that you’re ‘cured’ now because the cancer’s
been removed surgically. But then you’ve got this risk of
recurrence. I found that quite difﬁcult to wrestle in my
head because it doesn’t feel like I’m cured. It feels like
I’ve got cancer and I’ve got to see what happens over
the next ﬁve years…” (s8). “But that has been my
problem. Even taking the chemotherapy, if you’re
talking about, well if cancer, prone to cancer. If cancer
will come and chemotherapy wouldn’t…. if it were
there, I agree it would affect it, but if you will come back
I don’t think chemotherapy can stop it. That’s my
understanding; maybe I’m wrong” (s9). But some
patients did not think their cancer would come back,
and this belief seemed to be the basis of their decision
to refuse chemotherapy: “I’m sure that if I thought
there was a possibility of it coming back, for me, I
would…. I would go for treatment. But I’m just hoping
that it doesn’t happen” (s12).
DISCUSSION
We developed a DA for patients with stage II colorectal
cancer to facilitate an informed decision process for
adjuvant chemotherapy. Patient perceptions of the use-
fulness of the DA were above scores reported in other
patient groups,35 but there was evidence of a lack of
understanding of key information among some patients,
in particular: their baseline risk of recurrence, the net
beneﬁt of combination chemotherapy and the rationale
for having chemotherapy when cancer had apparently
gone.
The method of communicating risk of recurrence
information based on Adjuvant!online improves patient
understanding of the likelihood of disease-free sur-
vival.15 Numeric information about risks enhances
patient understanding.38 While visual displays can be
very helpful, not everyone can extract the relevant infor-
mation from them.31 Consistent with previous
research,15 we found that despite presenting numeric
and visual risk information, there was evidence of a lack
of understanding of risk information among some
patients.
Research on members of the general population has
shown that understanding of the graphical risk
information given in Adjuvant! online is improved if
people are presented with fewer options at any one
time,39 and that sequential presentation of treatment
options leads to improved understanding of key informa-
tion about risk of recurrence and net beneﬁt of treat-
ment.40 In this study, patients were presented with all
three options at once, and patient understanding of
combination chemotherapy might have been enhanced
by presenting just two options at a time (eg, no treat-
ment vs one drug, no treatment vs two drugs). In add-
ition, any beneﬁt of single agent chemotherapy has only
been observed among patients with bad prognostic
factors,4 which may be limited to T4.41 42 Signiﬁcant
efforts are being made to develop better prognostic indi-
cators including the search for gene signature sets that
predict response to chemotherapy in this patient
group.43 44 This suggests that, in future, even more
complex information may need to be presented to
patients.
The values clariﬁcation exercise required patients to
select arguments for and against chemotherapy.
Although the pros and cons method is the most com-
monly used method for values clariﬁcation purposes, a
variety of different methods are available, such as
ranking, and social matching (how another person
values the characteristics of different options and how
similar that person is to you), but owing to a lack of
research, there are no explicit recommendations about
best practice, and no ﬁrm evidence about how and
whether values clariﬁcation exercises actually inform
and help the decision-making process.45 Patient feed-
back showed that some patients found the exercise
useful, and for one clariﬁed the bottom line of the deci-
sion: prolonging life versus experiencing side effects.
However, for others, the process was less helpful, either
because understanding of the information contained in
the DA had effectively been delegated to a younger
member of the family (niece/son) or because the risk of
recurrence information was all they felt they needed to
make a decision. There is a lack of research about which
patients may beneﬁt from values clariﬁcation exercises,
and the best methods to engage people with different
cognitive ability or lower literacy levels and these issues
remain to be explored.45 The values clariﬁcation exer-
cise used in this study had a higher than recommended
readability level, and a simpler method of eliciting
patient preferences will be needed for patients with
lower levels of literacy.
A further suggested modiﬁcation of the DA is the add-
ition of information that helps people understand the
rationale for being given chemotherapy when cancer
has apparently gone. The information booklet devel-
oped by Jefford et al10 included diagrams showing how
colorectal cancer can spread around the body, and
similar information should be included in a revised DA.
A key limitation of this study is that patients educated
to degree-level or above were over-represented, which
may have led to an overestimate of perceived usefulness
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and acceptability of the DA as measured by the PrepDM
and other questionnaire items.
The American Cancer Society estimated that a third of
people diagnosed with colon cancer in 2013 will be diag-
nosed at stage II,8 resulting in a substantial number of
patients potentially faced with making a decision about
adjuvant chemotherapy. It is clear that challenges
remain in communicating risk of relapse information to
patients and the need to check patient understanding of
key information should be integrated in future DAs, for
example, with the insertion of quizzes and representa-
tion of key information that patients appear to have mis-
understood. In addition, much more research is needed
into the best way to facilitate patients in making judge-
ments about what is most important to them through a
greater understanding of values clariﬁcation methods in
assisting complex decisions.
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